Amgen

Open: 276.27 Close: 275.45 Change: -0.82

7 risks of investing in Amgen Company Inc Stock found by an AI after reading the whole internet.

Are looking for the most relevant information about Amgen? Investor spend a lot of time searching for information to make investment decisions in Amgen. This task is often burdensome and consumes huge amounts of free time. It also leads to mistakes due to fatigue and bounded rationality. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Amgen are: Amgen, executive, join, Reese, Bradner, James, innovation, and the most common words in the summary are: amgen, news, clinical, innovation, science, overview, patient, . One of the sentences in the summary was: Amgen has received the US Food and Drug Administration (FDA) priority review for its …

Concept Map

Semantic Network

Stock Summary

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's products include Enbrel, Prolia, Xgeva, Otezla, Aranesp, and Repatha..

Today's Summary

Amgen recorded $6.5 billion in product sales from July through September, a 5% increase from the same three-month period in 2022. Amgen has received the US Food and Drug Administration (FDA) priority review for its biologics licence application (BLA) for tarlatamab to treat advanced small cell lung cancer.

Today's News

Jay Bradner returns, now leading Amgens R&D effort, with Reese moving to CTO Amgen. Reese will be responsible for widening the companys use of AI and machine learning to the entire organization. Amgen recorded $6.5 billion in product sales from July through September, a 5% increase from the same three-month period in 2022. James Bradner has joined Amgen as executive vice president of Research and Development, and chief scientific officer at Amgen. Amgen has received the US Food and Drug Administration (FDA) priority review for its biologics licence application (BLA) for tarlatamab to treat advanced small cell lung cancer (SCLC) Amgen receives fda priority review. Amgen announces executive appointments to accelerate innovation. James Bradner joins as executive vice president of Research and Development, and chief scientific officer. David M. Reese joined Amgen in 2005 and has led the R&D organization. Amgen announces executive appointments to accelerate innovation. James Bradner joins as executive vice president of Research and Development, and chief scientific officer. David M. Reese joined Amgen in 2005 and led the R&D organization since 2018. Amgen announced that its Board of Directors declared a $2.25 per share dividend for the first quarter of 2024. This is the 12th consecutive year that Amgen has increased its dividend. Amgen announces executive appointments to accelerate innovation. James Bradner has joined Amgen as executive vice president of Research and Development, and chief scientific officer. James Bradner will be responsible for advancing Amgens pipeline of potential first-in-class medicines. David M. Reese joined Amgen in 2005 and has led the R&D organization since 2018. Reese has been instrumental in driving a culture of innovation over his 18-year tenure. Amgen announces executive appointments to accelerate innovation to accelerate. James Bradner joins as executive vice president of Research and Development, and chief scientific officer. David M. Reese has led the R&D organization since 2018. Amgen announces two changes to its senior leadership team in the areas of research and development (R&D) and technology. James Bradner joins as executive vice president of Research and Development, and chief scientific officer. David M. Reese joined Amgen in 2005 and has led the R&D organization since 2018. Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. Amgen has built an organization distinguished by world-class scientists with a talent for applying novel approaches to treat disease. European pharmaceutical firm AstraZeneca purchases Amgens Longmont campus for $64.5 million. Amgen announces executive appointments to accelerate innovation. Amgen Inc. stock outperforms competitors despite losses on the day. Amgen announces executive appointments to accelerate innovation. Amgen announces executive appointments to accelerate innovation. James Bradner joins as Executive Vice President, Research and Development, and Chief Scientific Officer. David M. Reese is executive vice president and chief technology officer. Amgen announces executive appointments to accelerate innovation. James Bradner joins as Executive Vice President, Research and Development, and Chief Scientific Officer. David M. Reese joined Amgen in 2005 and has led the R&D organization since 2018. James Bradner, M.D., joins as Executive Vice President, Research and Development, and Chief Scientific Officer. David M. Reese joined Amgen in 2005 and has led the R&D organization since 2018. Reese has been instrumental in driving a culture of innovation. Amgen announces executive appointments to accelerate innovation. James Bradner joins as executive vice president of Research and Development, and chief scientific officer. David M. Reese has led the R&D organization since 2018. Amgen announces executive appointments to accelerate innovation. James Bradner joins as executive vice president, Research and Development, and chief scientific officer. David M. Reese has led the R&D organization since 2005 and has led Amgen in 2005. Amgen Inc.s market capitalization is $149.52 B by 535.18 M shares outstanding. Amgen stock has received a consensus rating of buy. The 68 analysts offering price forecasts for Amgen have a median target of 262.50.

Stock Profile

"Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California."

Keywords

This document will help you to evaluate Amgen without reading an infinite amount of sources. Relying only on stock quotes or prices to make investment decisions is a mistake. Analyzing and observing stock charts, highs and lows and other numerical data does not allow to evaluate the real value of a company. Stock quotes and prices are the result of underlying characteristics of a company and of events and news happening around them. For this reason, investing must be based on information, not numbers. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Amgen are: Amgen, executive, join, Reese, Bradner, James, innovation, and the most common words in the summary are: amgen, news, clinical, innovation, science, overview, patient, . One of the sentences in the summary was: Amgen has received the US Food and Drug Administration (FDA) priority review for its biologics licence application (BLA) for tarlatamab to treat advanced small cell lung cancer.. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #amgen #news #clinical #innovation #science #overview #patient.